PMD9 A Comparative Assessment of Cost Implications of Novel Drug Versus Novel Device-Based Treatments for Stroke Prevention in Atrial Fibrillation
PMD9 A Comparative Assessment of Cost Implications of Novel Drug Versus Novel Device-Based Treatments for Stroke Prevention in Atrial Fibrillation is a paper indexed in PICO Portal from OpenAlex.
How many citations does PMD9 A Comparative Assessment of Cost Implications of Novel Drug Versus Novel Device-Based Treatments for Stroke Prevention in Atrial Fibrillation have?
PMD9 A Comparative Assessment of Cost Implications of Novel Drug Versus Novel Device-Based Treatments for Stroke Prevention in Atrial Fibrillation has 1 citations in the OpenAlex counts PICO Portal stores.
When was PMD9 A Comparative Assessment of Cost Implications of Novel Drug Versus Novel Device-Based Treatments for Stroke Prevention in Atrial Fibrillation published?
PMD9 A Comparative Assessment of Cost Implications of Novel Drug Versus Novel Device-Based Treatments for Stroke Prevention in Atrial Fibrillation has 2012 year in the PICO Portal index.
What is the open-access status of PMD9 A Comparative Assessment of Cost Implications of Novel Drug Versus Novel Device-Based Treatments for Stroke Prevention in Atrial Fibrillation?
PMD9 A Comparative Assessment of Cost Implications of Novel Drug Versus Novel Device-Based Treatments for Stroke Prevention in Atrial Fibrillation has closed oa status in the PICO Portal index.
What is the DOI of PMD9 A Comparative Assessment of Cost Implications of Novel Drug Versus Novel Device-Based Treatments for Stroke Prevention in Atrial Fibrillation?
The DOI for PMD9 A Comparative Assessment of Cost Implications of Novel Drug Versus Novel Device-Based Treatments for Stroke Prevention in Atrial Fibrillation is on the source record.
What is the OpenAlex record for PMD9 A Comparative Assessment of Cost Implications of Novel Drug Versus Novel Device-Based Treatments for Stroke Prevention in Atrial Fibrillation?
The OpenAlex for PMD9 A Comparative Assessment of Cost Implications of Novel Drug Versus Novel Device-Based Treatments for Stroke Prevention in Atrial Fibrillation is on the source record.